Terms: = Prostate cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
35 results:
1. Trends in Survival and Surgical Methods in Patients Surgically Treated for Metastatic Spinal Tumors: 25-Year Experience in a Single Institution.
Park SJ; Park JS; Lee CS; Kang BJ; Jung CW
Clin Orthop Surg; 2023 Feb; 15(1):109-117. PubMed ID: 36778984
[TBL] [Abstract] [Full Text] [Related]
2. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract] [Full Text] [Related]
3. Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis.
Sheng M; Guo S; Liu C
World J Surg Oncol; 2021 Dec; 19(1):345. PubMed ID: 34903228
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on treatment of Castration-Resistant prostate cancer.
Mizuno K; Sumiyoshi T; Okegawa T; Terada N; Ishitoya S; Miyazaki Y; Kojima T; Katayama H; Fujimoto N; Hatakeyama S; Shiota M; Yoshimura K; Matsui Y; Narita S; Matsumoto H; Kurahashi R; Kanno H; Ito K; Kimura H; Kamiyama Y; Sunada T; Goto T; Kobayashi T; Yamada H; Tsuchiya N; Kamba T; Matsuyama H; Habuchi T; Eto M; Ohyama C; Ito A; Nishiyama H; Okuno H; Kamoto T; Fujimoto A; Ogawa O; Akamatsu S
Clin Cancer Res; 2021 Nov; 27(22):6164-6173. PubMed ID: 34526361
[TBL] [Abstract] [Full Text] [Related]
5. Association of prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk prostate cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract] [Full Text] [Related]
6. cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract] [Full Text] [Related]
7. Association between Site-of-Care and the Cost and Modality of Radiotherapy for prostate cancer: Analysis of Medicare Beneficiaries from 2015 to 2017.
Tringale KR; Gennarelli RL; Gillespie EF; Mitchell AP; Zelefsky MJ
Cancer Invest; 2021 Feb; 39(2):144-152. PubMed ID: 33416007
[TBL] [Abstract] [Full Text] [Related]
8. TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the treatment of Solid Tumors.
Austin RJ; Lemon BD; Aaron WH; Barath M; Culp PA; DuBridge RB; Evnin LB; Jones A; Panchal A; Patnaik P; Ramakrishnan V; Rocha SS; Seto P; Sexton K; Strobel KL; Wall R; Yu S; Yu TZ; Law CL; Baeuerle PA; Wesche H
Mol Cancer Ther; 2021 Jan; 20(1):109-120. PubMed ID: 33203731
[TBL] [Abstract] [Full Text] [Related]
9. Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates.
Golan R; Patel NA; Sun T; Barbieri CE; Sedrakyan A; Kashanian JA
J Sex Med; 2018 Nov; 15(11):1653-1658. PubMed ID: 30415817
[TBL] [Abstract] [Full Text] [Related]
10. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract] [Full Text] [Related]
11. A Comparative Analysis of Survival and Funding Discrepancies in cancers With High Mortality.
Hall BR; Cannon A; Atri P; Wichman CS; Smith LM; Kumar S; Batra SK; Wang H; Ganti AK; Sasson AR; Are C
Ann Surg; 2020 Feb; 271(2):296-302. PubMed ID: 30188400
[TBL] [Abstract] [Full Text] [Related]
12. Survival analysis of malignant epidural spinal cord compression after palliative radiotherapy using Tokuhashi scoring system and the impact of systemic therapy.
Mui WH; Lam TC; Wong FCS; Sze WK
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S132-S139. PubMed ID: 29156895
[TBL] [Abstract] [Full Text] [Related]
13. Establishment of Korean prostate cancer database by the Korean Urological Oncology Society.
Ahn H; Kim HJ; Jeon SS; Kwak C; Sung GT; Kwon TG; Park JY; Paick SH
Investig Clin Urol; 2017 Nov; 58(6):434-439. PubMed ID: 29124243
[TBL] [Abstract] [Full Text] [Related]
14. cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Haruyama Y; Kobashi G; Ebner DK; Akakura K; Suzuki H; Ichikawa T; Shimazaki J; Makishima H; Nomiya T; Kamada T; Tsujii H;
Cancer Sci; 2017 Dec; 108(12):2422-2429. PubMed ID: 28921785
[TBL] [Abstract] [Full Text] [Related]
15. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M
J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
[TBL] [Abstract] [Full Text] [Related]
16. Randomized Trial of a Hypofractionated Radiation Regimen for the treatment of Localized prostate cancer.
Catton CN; Lukka H; Gu CS; Martin JM; Supiot S; Chung PWM; Bauman GS; Bahary JP; Ahmed S; Cheung P; Tai KH; Wu JS; Parliament MB; Tsakiridis T; Corbett TB; Tang C; Dayes IS; Warde P; Craig TK; Julian JA; Levine MN
J Clin Oncol; 2017 Jun; 35(17):1884-1890. PubMed ID: 28296582
[TBL] [Abstract] [Full Text] [Related]
17. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.
Tseng CH
Oncotarget; 2017 Mar; 8(12):19057-19064. PubMed ID: 27661113
[TBL] [Abstract] [Full Text] [Related]
18. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract] [Full Text] [Related]
19. [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].
Eisenhardt A; Schneider T; Scheithe K; Colling C; Heidenreich A;
Urologe A; 2016 Feb; 55(2):176-83. PubMed ID: 26518305
[TBL] [Abstract] [Full Text] [Related]
20. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract] [Full Text] [Related]
[Next]
